{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T14:08:47Z","timestamp":1791554927385,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Sandy Daulton Fund"},{"name":"Development of a New Treatment for Small Cell Lung Cancer harboring Rare Molecular Alterations","award":["JP19ck0106289"],"award-info":[{"award-number":["JP19ck0106289"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.lungcan.2020.07.018","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T11:33:54Z","timestamp":1595417634000},"page":"221-228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Downregulation of CYLD promotes IFN-\u03b3 mediated PD-L1 expression in thymic epithelial tumors"],"prefix":"10.1016","volume":"147","author":[{"given":"Shigeki","family":"Umemura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianquan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joeffrey J.","family":"Chahine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhaskar","family":"Kallakury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Kyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Giaccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.lungcan.2020.07.018_bib0005","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1097\/JTO.0b013e3182745f73","article-title":"Thymoma-a clinico-pathological long-term study with emphasis on histology and adjuvant radiotherapy dose","volume":"7","author":"Harnath","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.07.018_bib0010","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/00001622-200009000-00007","article-title":"Thymoma","volume":"12","author":"M\u00fcller-Hermelink","year":"2000","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2020.07.018_bib0015","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.athoracsur.2009.08.074","article-title":"Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery","volume":"89","author":"Margaritora","year":"2010","journal-title":"Ann. Thorac. Surg."},{"issue":"3","key":"10.1016\/j.lungcan.2020.07.018_bib0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.lungcan.2020.07.018_bib0025","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2020.07.018_bib0030","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.lungcan.2020.07.018_bib0035","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/j.leukres.2011.02.024","article-title":"Somatic mutation of CYLD gene is rare in hematologic and solid malignancies","volume":"35","author":"Kim","year":"2011","journal-title":"Leuk. Res."},{"issue":"8","key":"10.1016\/j.lungcan.2020.07.018_bib0040","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/ng.3016","article-title":"A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors","volume":"46","author":"Petrini","year":"2014","journal-title":"Nat. Genet."},{"issue":"11","key":"10.1016\/j.lungcan.2020.07.018_bib0045","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/carcin\/bgx094","article-title":"The genomic and epigenomic landscape in thymic carcinoma","volume":"38","author":"Saito","year":"2017","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.lungcan.2020.07.018_bib0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/JTO.0000000000000397","article-title":"Massively parallel sequencing identifies recurrent mutations in TP53 in thymic carcinoma associated with poor prognosis","volume":"10","author":"Moreira","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.07.018_bib0055","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/76006","article-title":"Identification of the familial cylindromatosis tumour-suppressor gene","volume":"25","author":"Bignell","year":"2000","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.lungcan.2020.07.018_bib0060","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.bbagen.2018.05.016","article-title":"Catalytic domain mutation in CYLD inactivates its enzyme function by structural perturbation and induces cell migration and proliferation","volume":"1862","author":"Johari","year":"2018","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"1","key":"10.1016\/j.lungcan.2020.07.018_bib0065","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/imr.12309","article-title":"Linear ubiquitination in immunity","volume":"266","author":"Shimizu","year":"2015","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.lungcan.2020.07.018_bib0070","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1016\/j.celrep.2016.02.062","article-title":"CYLD limits Lys63- and Met1-Linked ubiquitin at receptor complexes to regulate innate immune signaling","volume":"14","author":"Hrdinka","year":"2016","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.lungcan.2020.07.018_bib0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/cr.2010.166","article-title":"Deubiquitinases in the regulation of NF-\u03baB signaling","volume":"21","author":"Harhaj","year":"2011","journal-title":"Cell Res."},{"issue":"9","key":"10.1016\/j.lungcan.2020.07.018_bib0080","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/embor.2008.136","article-title":"The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response","volume":"9","author":"Friedman","year":"2008","journal-title":"EMBO Rep."},{"issue":"4","key":"10.1016\/j.lungcan.2020.07.018_bib0085","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/cr.2016.40","article-title":"Ubiquitin signaling in immune responses","volume":"26","author":"Hu","year":"2016","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.lungcan.2020.07.018_bib0090","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/JTO.0b013e3182460f8f","article-title":"NUT rearrangement is uncommon in human thymic epithelial tumors","volume":"7","author":"Petrini","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"20","key":"10.1016\/j.lungcan.2020.07.018_bib0095","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1002\/cncr.25367","article-title":"Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas","volume":"116","author":"Zucali","year":"2010","journal-title":"Cancer"},{"issue":"7 Suppl. 3","key":"10.1016\/j.lungcan.2020.07.018_bib0100","doi-asserted-by":"crossref","first-page":"S1710","DOI":"10.1097\/JTO.0b013e31821e8cff","article-title":"The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms","volume":"6","author":"Detterbeck","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2020.07.018_bib0105","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/ijc.23335","article-title":"Establishment, characterization and drug sensitivity testing in primary cultures of human thymoma and thymic carcinoma","volume":"122","author":"Ehemann","year":"2008","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2020.07.018_bib0110","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/labinvest.2012.115","article-title":"Establishment and characterization of a novel cell line derived from human thymoma AB tumor","volume":"92","author":"G\u00f6kmen-Polar","year":"2012","journal-title":"Lab. Invest."},{"issue":"8","key":"10.1016\/j.lungcan.2020.07.018_bib0115","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","article-title":"PI3K as a potential therapeutic target in thymic epithelial tumors","volume":"11","author":"Alberobello","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.07.018_bib0120","first-page":"4909","article-title":"CYLD expression in benign, malignant and metastatic lesions of colorectal epithelium and its prognostic role in colorectal carcinoma","volume":"9","author":"Zhao","year":"2016","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.07.018_bib0125","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2019.01.019","article-title":"Surgical resection of SCLC: prognostic factors and the tumor microenvironment","volume":"14","author":"Zhao","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2020.07.018_bib0130","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio Cancer genomics portal: an open platform for exploring multidimensional Cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.lungcan.2020.07.018_bib0135","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.lungcan.2020.07.018_bib0140","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","article-title":"PD-1 as a potential target in cancer therapy","volume":"2","author":"McDermott","year":"2013","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.lungcan.2020.07.018_bib0145","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2020.07.018_bib0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung Cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"issue":"50","key":"10.1016\/j.lungcan.2020.07.018_bib0155","doi-asserted-by":"crossref","first-page":"20683","DOI":"10.1074\/jbc.M117.809053","article-title":"MicroRNA-155 induction via TNF-\u03b1 and IFN-\u03b3 suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells","volume":"292","author":"Yee","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.lungcan.2020.07.018_bib0160","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.lungcan.2020.07.018_bib0165","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2020.07.018_bib0170","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3389\/fimmu.2015.00650","article-title":"Receptor-interacting protein Kinase-2 inhibition by CYLD impairs antibacterial immune responses in macrophages","volume":"6","author":"Wex","year":"2016","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.lungcan.2020.07.018_bib0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003455","article-title":"CYLD enhances severe listeriosis by impairing IL-6\/STAT3-Dependent fibrin production","volume":"9","author":"Nishanth","year":"2013","journal-title":"PLoS Pathog."},{"issue":"12","key":"10.1016\/j.lungcan.2020.07.018_bib0180","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.cellsig.2016.08.014","article-title":"E3 ubiquitin ligase NKLAM ubiquitinates STAT1 and positively regulates STAT1-mediated transcriptional activity","volume":"28","author":"Lawrence","year":"2016","journal-title":"Cell. Signal."},{"issue":"257","key":"10.1016\/j.lungcan.2020.07.018_bib0185","doi-asserted-by":"crossref","first-page":"ra3","DOI":"10.1126\/scisignal.2003197","article-title":"Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling","volume":"6","author":"Yang","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.lungcan.2020.07.018_bib0190","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/ncomms1776","article-title":"CYLD negatively regulates transforming growth factor-\u03b2-signalling via deubiquitinating Akt","volume":"3","author":"Lim","year":"2012","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.lungcan.2020.07.018_bib0195","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1093\/nar\/gkz163","article-title":"GSK3\u03b2-SCFFBXW7\u03b1 mediated phosphorylation and ubiquitination of IRF1 are required for its transcription-dependent turnover","volume":"47","author":"Garvin","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.lungcan.2020.07.018_bib0200","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1159\/000485084","article-title":"Cylindromatosis (CYLD), a deubiquitinase, attenuates inflammatory signaling pathways by activating toll-like receptor 3 in human mesangial cells","volume":"42","author":"Imaizumi","year":"2017","journal-title":"Kidney Blood Press. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2020.07.018_bib0205","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2020.07.018_bib0210","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3389\/fonc.2019.01055","article-title":"Clinicopathologic significance and immunogenomic analysis of programmed death-ligand 1 (PD-L1) and programmed death 1 (PD-1) expression in thymic epithelial tumors","volume":"9","author":"Song","year":"2019","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.07.018_bib0215","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.athoracsur.2018.08.037","article-title":"Clinicopathologic features of thymoma with the expression of programmed death ligand 1","volume":"107","author":"Hakiri","year":"2019","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2020.07.018_bib0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.lungcan.2018.09.002","article-title":"Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma","volume":"125","author":"Wei","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.07.018_bib0225","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.anndiagpath.2018.03.012","article-title":"PD-L1 immuno-expression assay in thymomas: study of 84 cases and review of literature","volume":"34","author":"Guleria","year":"2018","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.lungcan.2020.07.018_bib0230","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.lungcan.2016.12.005","article-title":"Analysis of a panel of druggable gene mutations and of ALK and PD-L1expression in a series of thymic epithelial tumors (TETs)","volume":"104","author":"Tiseo","year":"2017","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2020.07.018_bib0235","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.athoracsur.2015.10.044","article-title":"Clinicopathologic and prognostic implications of programmed death ligand 1 expression in thymoma","volume":"101","author":"Yokoyama","year":"2016","journal-title":"Ann. Thorac. Surg."},{"issue":"3","key":"10.1016\/j.lungcan.2020.07.018_bib0240","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/JTO.0000000000000429","article-title":"Diffuse high intensity PD-L1 staining in thymic epithelial tumors","volume":"10","author":"Padda","year":"2015","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:47:50Z","timestamp":1759236470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220305420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":48,"alternative-id":["S0169500220305420"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.018","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Downregulation of CYLD promotes IFN-\u03b3 mediated PD-L1 expression in thymic epithelial tumors","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}